2cureX announces changes to the Board of Directors

2cureX, a pioneer in the use of 3D tumoroids for predicting cancer treatment efficacy, is implementing significant changes in its governance resulting in four Board members leaving the Board of Directors

The company is transitioning from a centralised model, where drug sensitivity testing is solely conducted in its Copenhagen laboratories, to a decentralised business model. This shift will enable IndiTreat testing at various hospitals throughout Europe and beyond.

Tonni Bülow-Nielsen, Chairman of the Board, explains, “This strategic evolution requires an adaptation in our Board of Directors and Management, introducing new expertise, connections, and insights that align with our evolving business approach.” He adds, “consequently, four Board members have chosen to depart. We are currently engaging with highly qualified individuals possessing extensive knowledge in Diagnostics and Medtech, aiming to significantly strengthen our Board in the near future.”

The exiting members, Povl-Andre’ Bendz, Camilla Huse Bondesson, Michael Schaeffer, and Michel Klimkeit, are concluding their lengthy service on the Board. Vice-Chairman and Founder Ole Thastrup expresses “deep appreciation for their contributions to 2cureX's development”.

You may also like

Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Manufacturing

Hovione nearly doubles pharmaceutical spray drying capabilities at Cork, Ireland facility

The CDMO's multi-million investment will allow it to significantly increase its spray drying capacity, which is necessary for inhaled and oral therapeutics
Manufacturing

CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex

Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
Manufacturing

Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority

The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
Manufacturing

Pharmaceutics International bolsters its prefilled syringe production capabilities

The aseptic and oral dosage CDMO has invested USD $3.6m into advanced labelling, fill/finish and automated visual inspection technologies at its Hunt Valley site in Maryland, US
Manufacturing

Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site

The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
Drug Delivery

Challenges and development perspectives of primary packaging for parenteral drugs

When talking about parenteral drugs, we usually refer to the administration of drugs by injection through the integument or directly into the circulation, says Andrea Sentimenti, Marketing & Innovation Director at Bormioli Pharma. The parenteral route – it could be intradermal, subcutaneous, intramuscular or intravenous – indeed allows a rapid effect, the administration of orally inactivated drugs, rapid intervention in emergencies, and the administration of nutritional solutions to patients who cannot feed themselves normally
Subscribe now